6 results about "Anorexia" patented technology

The present invention relates to the use of an s100a8 / a9 and complement 3 inhibitor in the preparation of a drug for treating or preventing cachexia. The treatment or prevention of cachexia comprises increasing the body weight, lean body mass and fat mass, and increasing food intake in a cachectic subject, or preventing fat mass consumption, slowing the rate of body weight loss, the rate of fat mass loss and the rate of lean body mass loss, counteracting anorexia, muscle strength loss, fatigue and body weight loss, or improving abnormal biochemical results. Provided is a new understanding for the mechanism of energy balance regulation in cancer cachexia, with an emphasis on the effects of S100a8 / a9 and C3 in cancer cachexia. The inhibition of S100a8 / a9 and complement 3 can promote fat recovery and increase food intake. Particularly, it is verified that an S100a8 / a9 inhibitor can prevent body weight loss, especially adipose tissue loss, in a cachectic subject, and significantly increases food intake in the subject.

Provided herein are methods of treating, preventing, or reducing conditions and / or side effects associated with anti-cancer agents (e.g., chemotherapeutic agents) via administration of a non-naturally occurring melanocortin analog prior to, during, and / or after administration of the anti-cancer agents. The methods reduce adverse effects associated with the anti-cancer agent, such as anorexia, weight loss, muscle mass loss, fat mass loss, wasting, reduced appetite, and loss of appetite, thereby enhancing tolerance of the anti-cancer agents and survival of the subject having cancer or having a disease or condition that is not cancer but is treated, reduced, or prevented by administration of an anti-cancer agent.

This invention relates to the use of S100a8 / a9 and complement 3 inhibitors in the preparation of medicaments for the treatment or prevention of cachexia, wherein the treatment or prevention of cachexia involves increasing the body weight, lean body mass, fat mass, and food intake of cachectic subjects, or preventing fat loss, slowing the rate of weight loss, slowing the rate of fat mass loss, slowing the rate of lean body mass loss, resisting anorexia, resisting muscle weakness, resisting fatigue, resisting weight loss, and improving abnormal biochemical results. This invention provides a new understanding of the mechanism of energy balance regulation in cancer cachexia, focusing on the roles of S100a8 / a9 and C3 in cancer cachexia. This invention finds that inhibiting S100a8 / a9 and complement 3 can promote fat recovery and increase food intake. In particular, it demonstrates that S100a8 / a9 inhibitors can prevent the loss of body weight, especially adipose tissue, in cachectic subjects and significantly increase their food intake.

The application discloses a longevity tonic and a preparation method thereof, and belongs to the technical field of Chinese herbal medicines. The compound oral liquid is composed of 13 medicinal materials such as yam, fried hawthorn, prepared rehmannia, codonopsis, and poria cocos, adopts a water vapor distillation, double decoction, alcohol precipitation and concentration process, and a stabilizer is added before the decoction liquid is fixed in volume. The stabilizer takes wheat starch as raw material, is subjected to mild enzymolysis through a compound enzyme, is subjected to esterification modification through an acid anhydride compound under the assistance of ultrasonic, is blended with chitosan and biological powder, and is formed into the stabilizer through electrostatic self-assembly. Compared with the prior art, the longevity tonic can significantly inhibit the oxidation and thermal degradation of volatile oil, prolong the shelf life, realize the gastrointestinal slow release of active ingredients, and improve the bioavailability. The longevity tonic is used for treating qi and blood deficiency, regulating the spleen and stomach, and has good effects on old debilitation, post-illness asthenia, fatigue, anorexia, limb pain and numbness, and insomnia and dreaminess.

This invention discloses a method for quantitative feeding of donkeys applied in the field of animal husbandry. This method uses RFID identification technology to open feeding positions, achieving one feeding position per donkey. Based on this, the feeding time, feeding speed, and uneaten amount of each donkey are monitored, and the feeding amount for the next meal is dynamically adjusted. Compared with the prior art, this method can effectively achieve precise feeding of individual donkeys, avoiding feed waste caused by overeating or anorexia. At the same time, the one-donkey-one-feeding method effectively protects the weaker individuals in the donkey herd. Furthermore, by setting the feeding position as a semi-enclosed and independent area, it can not only effectively avoid mutual interference between donkeys during feeding, but also effectively prevent the dominant donkeys from taking the feeding positions of the weaker donkeys after they have finished eating. Physical means can be used to drive away the donkeys that are fighting for food. Compared with the prior art, this method can protect the weaker donkeys that need to be given extra nutrition or medication.

Methods and compositions for preventing, reducing, delaying, or reversing effects due to aging or preventing, treating, or reducing time to recovery from a disease associated with aging, as well as anemia, hypoalbuminemia, hypocholesterolemia, malnutrition / anorexia / starvation, and / or splenomegaly in a subject in need thereof are disclosed. The method can include administering a therapeutically effective amount of a ketogenic supplement to the subject, wherein the subject is fed ad libitum. The ketogenic supplement can include R,S 1,3-butanediol acetoacetate diester or derivatives thereof.